Bridge­Bio team clears a key hur­dle with their proof-of-con­cept da­ta for a rare ge­net­ic dis­ease. And they can thank the NIH for a quick suc­cess

Bridge­Bio’s Cal­ci­lytix team has sev­er­al good rea­sons to of­fer some spe­cial thanks to the NIH to­day.

Mike Collins, an NIH re­searcher and di­vi­sion chief who spe­cial­izes in bone and min­er­al me­tab­o­lism, sug­gest­ed the idea that the right cal­ci­um sens­ing re­cep­tor (CaSR) an­tag­o­nist could pro­vide a di­rect way to treat a rare dis­ease called ADH1, a ge­net­ic ail­ment that trig­gers a dan­ger­ous im­bal­ance in cal­ci­um in a small pa­tient pop­u­la­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER